Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice-Reference-Cited by-同舟云学术

Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice

Published:2018-12-07 Issue:1 Volume:2 Page:e104
ISSN:2398-8835
Container-title:Health Science Reports
language:en
Short-container-title:Health Sci Rep

Author:

Hulin Cyrille¹^ORCID,de la Rubia Javier²,Dimopoulos Meletios A.³,Terpos Evangelos³^ORCID,Katodritou Eirini⁴,Hungria Vania⁵^ORCID,De Samblanx Hadewijch⁶,Stoppa Anne-Marie⁷,Aagesen Jesper⁸,Sargin Deniz⁹,Sioni Anastasia³,Belch Andrew¹⁰,Diels Joris¹¹,Olie Robert A.¹²,Robinson Don¹³,Potamianou Anna¹⁴,van de Velde Helgi¹⁵,Delforge Michel¹⁶

Affiliation:

1. Service d'Hématologie Hôpital Haut-Lévêque; CHU; Bordeaux France

2. Department of Hematology, Hospital Dr Peset; Universidad Católica de Valencia; Valencia Spain

3. Department of Clinical Therapeutics; National and Kapodistrian University of Athens School of Medicine; Athens Greece

4. Department of Hematology, Theagenion Cancer Centre; Thessaloniki Greece

5. Santa Casa de São Paulo Medical School; São Paulo Brazil

6. Hematology, St Dimpna Hospital; Geel Belgium

7. Département D'Onco-Hématologie; Institut Paoli-Calmettes; Marseilles France

8. Department of Medicine, Ryhov County Hospital; Jönköping Sweden

9. Division of Hematology, Department of Internal Medicine; Istanbul University; Istanbul Turkey

10. Department of Oncology; Cross Cancer Institute; Edmonton AB Canada

11. Janssen Research and Development, Division of Janssen Pharmaceutica NV; Beerse Belgium

12. Janssen-Cilag AG; Zug Switzerland

13. Janssen Global Services; Raritan NJ USA

14. Janssen-Cilag Pharmaceutical SACI; Athens Greece

15. Millennium Pharmaceuticals, Inc., Cambridge, MA, USA; a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

16. Department of Hematology; University Hospital Leuven; Leuven Belgium

Funder

Janssen Global Services, LLC

Millennium Pharmaceuticals, Inc.

Publisher

Wiley

Subject

General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hsr2.104/fullpdf

Reference47 articles.

1. Current therapeutic strategy for multiple myeloma;Suzuki;Jpn J Clin Oncol,2013

2. Clinical course of patients with relapsed multiple myeloma;Kumar;Mayo Clin Proc,2004

3. How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions;Offidani;Expert Opin Investig Drugs,2011

4. Multiple myeloma;Dimopoulos;Ann Oncol,2010

5. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents;Mohty;Leukemia,2012

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epigenetic Alterations as Vital Aspects of Bortezomib Molecular Action;Cancers;2023-12-23

2. Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial;Clinical Cancer Research;2023-10-09

3. siRNA Lipid–Polymer Nanoparticles Targeting E-Selectin and Cyclophilin A in Bone Marrow for Combination Multiple Myeloma Therapy;Cellular and Molecular Bioengineering;2023-08

4. A case of multiple myeloma diagnosed by extramedullary disease in the submandibular region;Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology;2023-05

5. Identification and Targeting of Mutant Neoantigens in Multiple Myeloma Treatment;Current Oncology;2023-04-29